

Amendments to the Claims:

1 – 54. (Canceled)

55. (Previously Presented) A method of identifying a candidate therapeutic compound, said method comprising the steps of (a) contacting a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:6, or a fragment thereof comprising amino acids 469-518 of SEQ ID NO:6 or amino acids 739-748 of SEQ ID NO:6, with a test compound, wherein said test compound specifically binds to the polypeptide comprising the sequence of SEQ ID NO:6, or the fragment comprising amino acids 469-518 of SEQ ID NO:6 or amino acids 739-748 of SEQ ID NO:6; and (b) determining whether said test compound induces apoptosis of said cell and not of a control cell contacted with said test compound, wherein a test compound that induces apoptosis of said cell and not of said control cell is a candidate therapeutic compound.

56. (Previously Presented) The method of claim 55, wherein said fragment comprises amino acids 469-518 of SEQ ID NO:6 and amino acids 739-748 of SEQ ID NO:6.

57. (Original) The method of claim 55, wherein said cell is adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201).

58. (Previously Presented) The method of claim 56, wherein said fragment comprises a contiguous sequence of SEQ ID NO:6, wherein said contiguous sequence comprises amino acids 469-518 of SEQ ID NO:6 and amino acids 739-748 of SEQ ID NO:6.

59. (New) The method of claim 55, wherein said test compound is an antibody or an antibody fragment.

60. (New) The method of claim 59, wherein said test compound is an antibody fragment.

61. (New) The method of claim 59, wherein said antibody or antibody fragment is a human antibody or a human antibody fragment.

62. (New) The method of claim 55, wherein said cell is a stomach carcinoma cell.